We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $192M invested in AEON Biopharma in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

24% more funds holding

Funds holding: 59 → 73 (+14)

12% more capital invested

Capital invested by funds: $172M → $192M (+$20.2M)

0.2% more ownership

Funds ownership: 0.79% → 0.99% (+0.2%)

Holders
73
Holders Change
+14
Holders Change %
+23.73%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
14
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$6.57M
2
KIM
Karpus Investment Management
New York
+$4.51M
3
Millennium Management
Millennium Management
New York
+$3.74M
4
JP Morgan Chase
JP Morgan Chase
New York
+$2.67M
5
PC
Periscope Capital
Ontario, Canada
+$2.5M

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.92M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$2.44M
3
WAM
Wolverine Asset Management
Illinois
-$1.72M
4
SC
Sculptor Capital
New York
-$1.46M
5
CL
CSS LLC
Illinois
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
COPPSERS
51
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$486K – – –
TCM
52
Tegean Capital Management
New York
$486K +$488K +694 New
RCM
53
Rivernorth Capital Management
Florida
$389K – – –
NAM
54
Nexpoint Asset Management
Texas
$386K -$13.4K -19 -3%
BCM
55
Basso Capital Management
Connecticut
$371K – – –
GH
56
GAM Holding
Switzerland
$325K +$327K +465 New
DFCM
57
Dark Forest Capital Management
Puerto Rico
$317K +$319K +454 New
CC
58
Centiva Capital
New York
$294K – – –
ICMH
59
Integrity Capital Management (HK)
Hong Kong
$291K +$293K +417 New
WRBC
60
W.R. Berkley Corp
Connecticut
$244K – – –
CCM
61
Cinctive Capital Management
New York
$243K – – –
Citigroup
62
Citigroup
New York
$243K +$244K +347 New
CSS
63
Cubist Systematic Strategies
Connecticut
$232K +$233K +332 New
RCM
64
Robinson Capital Management
Michigan
$210K +$109K +155 +107%
TI
65
Tidal Investments
Wisconsin
$210K +$109K +155 +107%
Qube Research & Technologies (QRT)
66
Qube Research & Technologies (QRT)
United Kingdom
$165K +$58.4K +83 +55%
AA
67
Ancora Advisors
Ohio
$163K – – –
PCM
68
Pinz Capital Management
New York
$138K +$139K +197 New
KKRC
69
Kohlberg Kravis Roberts & Co
New York
$102K +$103K +146 New
6CM
70
683 Capital Management
New York
$98K – – –
GCL
71
Glazer Capital LLC
New York
$25K – – –
WAM
72
Wolverine Asset Management
Illinois
$8K -$1.72M -2,439 -99%
TRCT
73
Tower Research Capital (TRC)
New York
$2K +$1.41K +2 New
PAMP
74
Polar Asset Management Partners
Ontario, Canada
– -$2.92M -4,167 Closed
SC
75
Sculptor Capital
New York
– -$1.46M -2,083 Closed
1 2
3
4

AEON Hedge Fund Activity: Q4 2021 in Review

73 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2021, worth a combined $192M — up 12% from $172M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AEON positions and 4 closed out — a net gain of 14 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Marshall Wace, adding an estimated $6.57M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.92M sold.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q4 2021, up from 59 in Q3 2021.
  • Funds reported $192M of AEON Biopharma stock for Q4 2021, up 12% quarter-over-quarter.
  • 18 funds opened new AEON Biopharma positions in Q4 2021 and 4 closed out, a net change of +14 holders.
  • The largest AEON Biopharma buyer in Q4 2021 was Marshall Wace, an estimated $6.57M added.
  • The largest AEON Biopharma seller in Q4 2021 was Polar Asset Management Partners, an estimated $2.92M sold.

Based on aggregated 13F filings for Q4 2021.